Teva Pharmaceutical Industries Ltd (TEVA)

pos +0.11
Today's Range: 32.31 - 32.69 | TEVA Avg Daily Volume: 8,153,300
Last Update: 07/24/17 - 10:43 AM EDT
Volume: 769,353
YTD Performance: -9.96%
Open: $32.44
Previous Close: $32.64
52 Week Range: $27.60 - $55.79
Oustanding Shares: 1,016,000,000
Market Cap: 32,948,880,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 5
Moderate Buy 1 1 1 1
Hold 10 10 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 1 1
Mean Rec. 2.40 2.40 2.50 2.40
Latest Dividend: 0.29
Latest Dividend Yield: 3.56%
Dividend Ex-Date: 06/01/17
Price Earnings Ratio: 6.31
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
6.31 0.00 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.85% -40.25% -39.89%
Revenue 11.50 0.10 0.03
Net Income -80.50 -0.80 -0.37
EPS -96.20 -0.90 -0.64
Earnings for TEVA:
Revenue 21.90B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.06 $1.22 $4.67 $4.61
Number of Analysts 4 4 6 6
High Estimate $1.07 $1.33 $4.90 $5.08
Low Estimate $1.04 $1.09 $4.34 $4.09
Prior Year $1.25 $1.28 $5.06 $4.67
Growth Rate (Year over Year) -15.20% -4.88% -7.77% -1.32%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
Bullish and bearish reversals for this week.

Teva Ready for Higher Prices Real Money Pro($)

The money flow has turned positive.
Prices are extended on the downside.

2 Biotech Pullback Targets Real Money Pro($)

Acadia and Neurocrine both have catalysts for growth; buy any weakness.
These stocks should be part of a strong first-quarter earnings season.
It will probably take a close above $38 to turn the chart more bullish.
These two large-cap drug giants should be core parts of any well-diversified portfolio.
Yes, he's unpredictable, but is that a reason to sell?


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.